Monopar Therapeutics Appoints New Chief Medical Officer
Ticker: MNPR · Form: 8-K · Filed: May 24, 2024 · CIK: 1645469
| Field | Detail |
|---|---|
| Company | Monopar Therapeutics (MNPR) |
| Form Type | 8-K |
| Filed Date | May 24, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $384,800 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, personnel
TL;DR
Monopar just hired a new CMO, Andy Mueller, to lead clinical trials.
AI Summary
Monopar Therapeutics Inc. announced on May 23, 2024, the appointment of Dr. Andrew "Andy" Mueller as Chief Medical Officer. Dr. Mueller, who previously served as Chief Medical Officer at Aptose Biosciences, will lead Monopar's clinical development strategy. This appointment is effective immediately.
Why It Matters
The appointment of a new Chief Medical Officer is crucial for guiding the company's clinical trial strategy and execution, potentially impacting the future development and success of its drug candidates.
Risk Assessment
Risk Level: medium — The appointment of a new executive, especially in a critical role like CMO, introduces a degree of uncertainty regarding future strategic direction and execution.
Key Players & Entities
- Monopar Therapeutics Inc. (company) — Registrant
- Andrew "Andy" Mueller (person) — Appointed Chief Medical Officer
- Aptose Biosciences (company) — Previous employer of Dr. Mueller
- May 23, 2024 (date) — Effective date of appointment
FAQ
Who has been appointed as the new Chief Medical Officer of Monopar Therapeutics?
Dr. Andrew "Andy" Mueller has been appointed as the new Chief Medical Officer of Monopar Therapeutics.
When was the appointment effective?
The appointment was effective as of May 23, 2024.
What was Dr. Mueller's previous role?
Dr. Mueller previously served as Chief Medical Officer at Aptose Biosciences.
What will be Dr. Mueller's primary responsibility at Monopar Therapeutics?
Dr. Mueller will lead Monopar's clinical development strategy.
What is Monopar Therapeutics' principal executive office address?
Monopar Therapeutics' principal executive office is located at 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091.
Filing Stats: 803 words · 3 min read · ~3 pages · Grade level 10.2 · Accepted 2024-05-24 08:00:10
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value MNPR The Nasdaq Stock Mar
- $384,800 — ishnan will receive an annual salary of $384,800, an annual target bonus of up to 35% of
Filing Documents
- mnpr20240523c_8k.htm (8-K) — 29KB
- ex_679388.htm (EX-99.1) — 10KB
- monologo.jpg (GRAPHIC) — 4KB
- 0001437749-24-018249.txt ( ) — 181KB
- mnpr-20240523.xsd (EX-101.SCH) — 3KB
- mnpr-20240523_def.xml (EX-101.DEF) — 12KB
- mnpr-20240523_lab.xml (EX-101.LAB) — 15KB
- mnpr-20240523_pre.xml (EX-101.PRE) — 12KB
- mnpr20240523c_8k_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On May 24, 2024, the Company issued a press release announcing the management changes described above. The press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits Exhibit No. Description 99.1 Press Release Dated May 24, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Monopar Therapeutics Inc. Date: May 24, 2024 By: /s/ Kim R. Tsuchimoto Name: Kim R. Tsuchimoto Title: Chief Financial Officer and Director